• Reyon Pharmaceutical cut its third-series convertible bond conversion price to KRW 10,170 from KRW 11,858, effective Oct. 16, 2026.
• The adjustment increases shares convertible from KRW 85 billion of outstanding bonds to 8,357,915 from 7,168,156.
• The reduction reflects issuance of fourth-series convertible bonds with a lower conversion price.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261016800511), on October 16, 2026, and is solely responsible for the information contained therein.